Abbott Laboratories vs Home Depot Inc — how do they compare? Abbott Laboratories trades at $109.13 (market cap $187.95B), while Home Depot Inc trades at $354.83 (market cap $349.77B). The key difference: Home Depot Inc is the larger of the two by market cap, and Home Depot Inc pays the higher dividend (2.66%). Which is the better fit depends on your goals.
| ABT | HD | |
|---|---|---|
Market Cap | $187.95B | $349.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $423.42 |
52-Week Low | $82.57 | $297.51 |
Enterprise Value | $214.96B | $411.32B |
Dividend Yield | 2.32% | 2.66% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Home Depot (HD) trades at $350.78, down 1.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company reported $159.51B in 2025 revenue with solid profitability metrics including 8.41% net income margin and 128.38% ROE. Recent earnings show mixed results with Q2 2026 expectations set at $4.73 EPS. The stock faces headwinds from weakening big-ticket demand and rising mortgage rates, but maintains strong analyst support with 59% buy ratings.
Home Depot presents a compelling long-term investment case with stable fundamentals and professional segment growth potential, though near-term challenges include housing market sensitivity and margin pressure. The consensus price target of $368.75 suggests 5.1% upside potential from current levels, supported by strong cash flow generation and dividend payments. Key risks include consumer spending volatility and competitive pressures in the home improvement sector.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →